



Neuren (NEU) – ASX Announcement

7 December 2020

Neuren investor briefing webinar

Melbourne, Australia: Neuren Pharmaceuticals (ASX: NEU) CEO Jon Pilcher & Chairman Patrick Davies will conduct an investor briefing webinar on Thursday 10 December 2020 commencing at 11.00 AEDT.

To participate in this free event, which is hosted by Monsoon Communications and sponsored by FB Rice, investors should register via the following link:

https://us02web.zoom.us/webinar/register/WN_8kbpXsDRSX6rfqTMsCAryA

About Neuren

Neuren is developing two new drug therapies to treat five serious neurological disorders that emerge in early childhood, none of which have any approved medicines.

The lead drug compound, trofinetide, is currently in a Phase 3 clinical trial for Rett syndrome and has completed a Phase 2 clinical trial in Fragile X syndrome. Because of the urgent unmet need, the programs have each been granted Fast Track designation by the US Food and Drug Administration (FDA) and “orphan drug” designation in both the United States and the European Union, a designation that provides incentives to encourage therapies for rare and serious diseases.

Neuren has granted an exclusive licence to ACADIA Pharmaceuticals Inc. for the development and commercialisation of trofinetide in North America, while retaining all rights outside North America.

Neuren is advancing the development of its second drug candidate NNZ-2591 for Phelan-McDermid, Angelman and Pitt Hopkins syndromes, each of which has received orphan drug designation in the United States and the European Union. Neuren has commenced a Phase 1 clinical trial of NNZ-2591 and plans to initiate Phase 2 trials in all three disorders in 2021.

Contacts:

Jon Pilcher, CEO: jpilcher@neurenpharma.com; +61 438 422 271

Rudi Michelson, Monsoon Communications: rudim@monsoon.com.au; +61 411 402 737

ASX Listing Rules information

This announcement was authorised to be given to the ASX by the CEO of Neuren Pharmaceuticals Limited, Suite 201, 697 Burke Road, Camberwell, VIC 3124